These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 11701896)
81. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Conway KA; Rochet JC; Bieganski RM; Lansbury PT Science; 2001 Nov; 294(5545):1346-9. PubMed ID: 11701929 [TBL] [Abstract][Full Text] [Related]
82. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. Li J; Zhu M; Manning-Bog AB; Di Monte DA; Fink AL FASEB J; 2004 Jun; 18(9):962-4. PubMed ID: 15059976 [TBL] [Abstract][Full Text] [Related]
84. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Lotharius J; Brundin P Nat Rev Neurosci; 2002 Dec; 3(12):932-42. PubMed ID: 12461550 [No Abstract] [Full Text] [Related]
85. Toxic effects of dopamine metabolism in Parkinson's disease. Hattoria N; Wanga M; Taka H; Fujimura T; Yoritaka A; Kubo S; Mochizuki H Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S35-8. PubMed ID: 19131041 [TBL] [Abstract][Full Text] [Related]
86. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Ahlskog JE Mov Disord; 2005 Mar; 20(3):271-82. PubMed ID: 15580550 [TBL] [Abstract][Full Text] [Related]
87. [Free radicals and ailing proteins--the culprits behind Parkinson disease?]. Smith R; Lotharius J; Brundin P Lakartidningen; 2003 Apr; 100(15):1324-6, 1329-30. PubMed ID: 12739402 [TBL] [Abstract][Full Text] [Related]
88. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Kostrzewa RM; Kostrzewa JP; Brus R Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519 [TBL] [Abstract][Full Text] [Related]
89. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? Maguire-Zeiss KA; Short DW; Federoff HJ Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526 [TBL] [Abstract][Full Text] [Related]
90. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. Sidhu A; Wersinger C; Vernier P FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042 [TBL] [Abstract][Full Text] [Related]
91. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease]. Klivényi P; Vécsei L Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097 [TBL] [Abstract][Full Text] [Related]
92. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease. Yokochi M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038 [TBL] [Abstract][Full Text] [Related]
93. Lewy bodies in Parkinson's disease: protectors or perpetrators? Harrower TP; Michell AW; Barker RA Exp Neurol; 2005 Sep; 195(1):1-6. PubMed ID: 16023637 [No Abstract] [Full Text] [Related]
94. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease. Zhu BT Int J Mol Med; 2004 Mar; 13(3):343-53. PubMed ID: 14767563 [TBL] [Abstract][Full Text] [Related]
95. Levodopa delivery systems for the treatment of Parkinson's disease: an overview. Goole J; Amighi K Int J Pharm; 2009 Oct; 380(1-2):1-15. PubMed ID: 19651197 [TBL] [Abstract][Full Text] [Related]